Boehringer Ingelheim and Saniona schizophrenia partnership advances to next stage
The firms are ready to take their two-year long collaboration to the next level.
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen
Boehringer Ingelheim and Saniona are advancing to the next stage of their partnership on a drug candidate within the schizophrenia indication, the latter firm announces in a press release on Monday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Saniona clears obstacle ahead of new trial
For subscribers
